Satipharm CBD

Satipharm CBD is a proprietary oral formulation of cannabidiol (CBD) developed by CANN Group Limited. The formulation utilizes patented Gelpell technology, which embeds full-spectrum hemp-derived CBD within seamless gelatin beads encased in a gastro-resistant capsule. This design protects the active cannabinoid from degradation in the stomach and ensures targeted release in the small intestine, significantly enhancing bioavailability compared to standard CBD oil preparations. Satipharm CBD has been clinically evaluated for the short-term treatment of mild sleep disturbance and insomnia in adults. In early 2023, CANN Group announced results from a Phase III randomized, double-blind, placebo-controlled trial involving 257 participants, which showed that the low-dose CBD capsules did not achieve statistical superiority over placebo for sleep disturbance. Prior to this, the product was available in Australia under the Special Access Scheme (Category B) and the Authorised Prescriber Scheme, and CANN Group had entered into an exclusive evaluation and option agreement with GSK Consumer Healthcare (Haleon) for its potential over-the-counter commercialization.

Brand names

Satipharm CBDSatipharm CBD Gelpell

Other names

Satipharm CBD capsulesSatipharm CBD Gelpell capsulesGelpell-CBD